- Phase 3 pivotal trial evaluating apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA on track to initiate by year-end 2021
- Update from Part A of the DRAGON Phase 1 trial evaluating SRK-181s ability to overcome primary resistance to checkpoint inhibitors being presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
- Initiated Part B dose expansion portion of the DRAGON trial
- U.S. patent issued providing additional product protection for SRK-181 to May 2040
CAMBRIDGE, Mass., November 09, 2021--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.
"The DRAGON trial addresses two key questions; first, can the selectivity of SRK-181 for TGF1 increase the therapeutic window for inhibition of this signaling pathway thereby enabling higher doses safely, and second, does SRK-181 exhibit anti-tumor activity effective in overcoming resistance to checkpoint inhibitors in solid tumors. We are pleased with the results of Part A, as will be provided this week at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and we look forward to exploring the efficacy dimension of our therapeutic hypothesis in Part B," said Nagesh Mahanthappa, Ph.D., Interim CEO of Scholar Rock. "Building on the momentum from the first half of this year, we are also excited about the progress with apitegromab and are on track to initiate by year-end the Phase 3 pivotal trial evaluating its efficacy in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA)."
Company Updates and Upcoming Milestones
Apitegromab is a selective inhibitor of myostatin activation being developed as the potential first muscle-directed therapy for the treatment of spinal muscular atrophy (SMA).
Additional Exploratory Responder Analyses and Pharmacologic Data from the TOPAZ Phase 2 Trial were Presented at Various Medical Congresses. In September 2021, two posters were presented at the World Muscle Society Virtual Congress, including a late-breaker poster featuring an exploratory analysis evaluating time to achieving various thresholds of improvement in Hammersmith Functional Motor Scale Expanded (HFMSE) scores, which are consistent with the observed dose response in clinical efficacy. In October 2021, a poster presented at the 25th World Congress of Neurology (WCN) described the positive correlation between the magnitude of target engagement and motor function improvements following apitegromab treatment. At the 50th Child Neurology Society Annual Meeting, additional exploratory responder analyses on Hammersmith scale scores were presented, including time to achieve different thresholds of improvement in HFMSE scores.
Phase 3 Trial Evaluating Apitegromab in Patients with Non-Ambulatory Type 2 and 3 Patients Remains on Track to Initiate by Year-End 2021. Scholar Rock is preparing to announce the design of the Phase 3 pivotal study later this month. The company is on track to initiate by the end of 2021 the randomized, double-blind, placebo-controlled Phase 3 trial evaluating apitegromab as add-on therapy for patients on either nusinersen or risdiplam with non-ambulatory Type 2 and Type 3 SMA. This patient population comprises an estimated two-thirds of the overall prevalence of SMA, and the greatest improvements in motor function (as measured by HFMSE) observed in the TOPAZ Phase 2 trial were in patients with non-ambulatory Type 2 and Type 3 SMA receiving apitegromab as add-on therapy to background nusinersen.
SRK-181 is a selective inhibitor of latent TGF1 activation being developed with the aim of overcoming primary resistance to and increasing the number of patients who may benefit from checkpoint inhibitor therapy.
Update from Part A of the DRAGON Phase 1 Trial and Part B Dose to be Presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. A poster titled, "First-in-Human Phase 1 Trial of SRK-181: A Latent TGF1 inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors (DRAGON trial)" will be presented at the SITC meeting on November 12, 2021. The poster will include initial clinical data from Part A of the DRAGON trial as well as the rationale for the identified Part B dose.
The Company has initiated the Part B dose expansion portion of the trial, which consists of multiple cohorts, each enrolling up to 40 patients with various solid tumors who have demonstrated primary resistance to anti-PD-(L)1 therapy.
U.S. Patent Issued Providing Composition of Matter Product Protection for SRK-181. In September 2021, the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,130,803 with an expiry of May 2040, including 313 days of Patent Term Adjustment (PTA). The European counterpart has also been granted.
Third Quarter 2021 Financial Results
For the quarter ended September 30, 2021, net loss was $37.5 million or $1.02 per share compared to a net loss of $23.6 million or $0.79 per share for the quarter ended September 30, 2020.
Revenue was $5.5 million for the quarter ended September 30, 2021, compared to $3.0 million for the quarter ended September 30, 2020 and was related to the Gilead Collaboration Agreement that was executed in December 2018.
Research and development expense was $31.3 million for the quarter ended September 30, 2021, compared to $18.4 million for the quarter ended September 30, 2020. The increase year-over-year primarily reflects manufacturing costs associated with apitegromab, clinical trial costs for SRK-181, and additional personnel and facility-related costs.
General and administrative expense was $11.3 million for the quarter ended September 30, 2021, compared to $8.3 million for the quarter ended September 30, 2020. The increase year-over-year was primarily attributed to additional personnel, professional fees, and facility-related costs.
"As we approach the end of 2021, I am incredibly proud of the execution by the entire Scholar Rock team this year. Not only have we initiated Part B of the DRAGON trial, but were also very close to initiating our Phase 3 pivotal trial for apitegromab," said Ted Myles, CFO and Head of Business Operations of Scholar Rock. "We ended the third quarter with approximately $246 million in cash and cash equivalents and are well-funded to continue executing on our development programs while continuing to invest in our robust discovery platform."
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rocks approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit http://www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).
Scholar Rock is a registered trademark of Scholar Rock, Inc.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rocks future expectations, plans and prospects, including without limitation, Scholar Rocks expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include preclinical and clinical data, including the results from the Phase 2 trial of apitegromab or Part A of the Phase 1 trial of SRK-181, are not predictive of, are inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including the planned Phase 3 trial of apitegromab in SMA and Part B of the Phase 1 trial of SRK-181, respectively, Scholar Rocks ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rocks nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rocks ability to obtain, maintain and protect its intellectual property, the success of Scholar Rocks current and potential future collaborations, including its collaboration with Gilead, Scholar Rocks dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, Scholar Rocks ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rocks Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rocks subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rocks views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
Scholar Rock Holding Corporation
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
Three Months Ended September 30
Nine Months Ended September 30
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense), net
Net loss per share, basic and diluted
- Marking 5 decades of progress in cancer care - Urology Times - January 5th, 2022
- Ranch group recognizes progress but skeptical of White House action plan - The Fence Post - January 5th, 2022
- Some signs of progress on Hogarth Ave. in Flint - ABC 12 News - January 5th, 2022
- Better Country Beyond: Progress ... and then the big freeze - The West Volusia Beacon - January 5th, 2022
- Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team - Business Wire - January 5th, 2022
- Legislative topic today is education. Bottom line: progress slight over last two decades. - Arkansas Times - January 5th, 2022
- 'PAUL' IT ALL TOGETHER: Resolutions And Empty Spaces - mvprogress - January 5th, 2022
- By the numbers: Biden reviews supply chain progress with task force - Supply Chain Dive - January 5th, 2022
- Resilient Kingston making progress while facing COVID, other challenges, mayor says in State of the City address - The Daily Freeman - January 5th, 2022
- Cowboy Ingenuity And A Steam Engine - The Progress - mvprogress - January 5th, 2022
- NC Coastal Federation recaps its progress, looks forward to 2022 - WNCT - January 5th, 2022
- Tolton girls basketball shows signs of progress in first win of the season - Columbia Daily Tribune - January 5th, 2022
- NYC wiped out five years of policing progress in 2021 - New York Post - January 5th, 2022
- City: Daylite Inn making progress on code violations - The Elkhart Truth - January 5th, 2022
- Women Directors Are Actually Losing Ground in Hollywood. Progress In Other Roles Is Glacial - LAist - January 5th, 2022
- The very slow progress on Hazard Center Road - San Diego Reader - January 5th, 2022
- SH Lions Hang On To Beat Bobcats - lexingtonprogress.com - January 5th, 2022
- Top stories of 2021 in the Jackson Progress-Argus, Part 1 - jacksonprogress-argus - January 5th, 2022
- Big Red Tigers Take Win Over Bulldogs - lexingtonprogress.com - January 5th, 2022
- First Snow of 2022 Preceded by Storms and Power Outages - lexingtonprogress.com - January 5th, 2022
- Battle of Parkers Crossroads Holds 159th Anniversary Event - lexingtonprogress.com - January 5th, 2022
- Tech trend review offers insight into the future - Farm Progress - January 5th, 2022
- Five Areas of Energy and Climate Progress to Watch for in 2022 - Energy Institute at Haas - January 5th, 2022
- Forward Progress And Texans Stopped - Sports Illustrated - January 3rd, 2022
- Don't Let Excellence Get in the Way of Progress - CPAPracticeAdvisor.com - January 3rd, 2022
- Progress Report: Thai Airways Slow But Steady Rehabilitation - Simple Flying - January 3rd, 2022
- Man City Youngster Keen On January Move Abroad to Progress Development - Club's Stance on Potential Sale Revealed - Sports Illustrated - January 3rd, 2022
- Brazil Mayor, Brian Wyndham, reflects on progress made in 2021 - WTHITV.com - January 3rd, 2022
- Will the Democratization of Technology Accelerate Progress in AI? - InformationWeek - January 3rd, 2022
- Progress made in Alzheimer's fight this year - Mount Airy News - January 3rd, 2022
- FROM THE HART: OSU's 'biggest win' shows progress and potential - Stillwater News Press - January 3rd, 2022
- The Seahawks offense is still a work-in-progress - Field Gulls - January 3rd, 2022
- Iran says nuclear talks in Vienna are seeing satisfactory progress - The Times of Israel - January 3rd, 2022
- Georgia Gov. Brian Kemp checks in on the progress of Hub Development - WJBF-TV - January 3rd, 2022
- A Dozen Things That Helped and Hurt Climate Progress in 2021 - State of the Planet - January 3rd, 2022
- Lithium: A year of progress and protests | Mining | elkodaily.com - Elko Daily Free Press - January 3rd, 2022
- Progress edition: Startups not deterred by the pandemic - Post Register - January 3rd, 2022
- Native American tribes have made progress against COVID. Omicron has them 'back in crisis mode.' - Yahoo News - January 3rd, 2022
- Dan Campbell is a throwback who is making progress as Lions head coach - SideLion Report - January 3rd, 2022
- Bill Belichick Sheds Light on Mac Jones Progress and Development as a Rookie QB - EssentiallySports - January 3rd, 2022
- Mayor Lightfoot reflects on City of Chicago's progress in 2021 - The - The Chicago Cusader - January 3rd, 2022
- Good News on the Progress of Alex Caruso - bleachernation.com - January 3rd, 2022
- 2021 Year-In-Review: Progress on Education, Health Care, Good Jobs & More - pa.gov - December 29th, 2021
- Where is NASA's James Webb Space Telescope? Here's how to follow its progress. - Space.com - December 29th, 2021
- US sees possible modest progress in Iran nuclear talks - The Times of Israel - December 29th, 2021
- Poland hopes for progress in talks with Czechs over Turow mine - Reuters - December 29th, 2021
- Department of Family & Preventive Medicine's Colorectal Screening Project Sees Progress in First Year - UAMS News - December 29th, 2021
- Montenegro: New Government, But No Progress on War Crime Probes - Balkan Insight - December 29th, 2021
- No One Asked Me But... (December 29, 2021) - The Progress - mvprogress - December 29th, 2021
- Malkin and Rust Progress to Full Contact; Six Players Enter Protocol - NHL.com - December 29th, 2021
- Letter: Resolving pandemic is a work in progress - La Grande Observer - December 29th, 2021
- Progress' most-read stories of 2021: New businesses, construction are some of the most read stories - Claremore Daily Progress - December 29th, 2021
- Davis Mills' progress will allow Texans to focus on other needs in draft - Chron - December 29th, 2021
- Oneida County asks for patience amid slow progress with vaccine incentives - WKTV - December 29th, 2021
- IDOT pleased with 2021 progress - Alton Telegraph - December 29th, 2021
- The progress of third-year corner Amani Oruwariye shows just how close the Detroit Lions are to turning things around | NFL News, Rankings and... - December 29th, 2021
- Palmhurst hosts second annual Toy Giveaway Drive-Thru - Progresstimes - December 29th, 2021
- DOT Secretary touts progress and predicts more to come - West Virginia MetroNews - December 29th, 2021
- A LOOK BACK AT 2021: The News In Review - mvprogress - December 29th, 2021
- New Smart Bins Show Citys Slow Progress On Composting Goals - Gothamist - December 29th, 2021
- Salon Expands Both Space And Staff - The Progress - mvprogress - December 29th, 2021
- Delivering Christmas Cheer To Hospital Patients - The Progress - mvprogress - December 29th, 2021
- U.S. aviation, telecom industries report progress over 5G safety talks - Reuters - December 29th, 2021
- Bidens Child-Poverty Progress Isnt Real - The Wall Street Journal - December 29th, 2021
- Spurs making progress but Conte still has a 'big job' on his hands - Reuters - December 29th, 2021
- 2021 Saw Progress on Mars, Rise in Space Tourists - VOA Learning English - December 29th, 2021
- Winning recipes in The Progress' 2021 Holiday Cookie Contest - Clearfield Progress - December 22nd, 2021
- UN envoy outlines 'possibilities for progress' in Syria next year - UN News - December 22nd, 2021
- Teven Jenkins is a Work in Progress, But You Gotta Love the Physicality - bleachernation.com - December 22nd, 2021
- The Vaccine Rollout Was a Success. But Events Within and Beyond Bidens Control Stymied Progress. - Kaiser Health News - December 22nd, 2021
- Where Rangers' top prospects stand and how much progress they're making - New York Post - December 22nd, 2021
- White House: People won't have to 'wear a mask all the time' if 'we make progress' fighting COVID - Fox News - December 22nd, 2021
- Carbon colonialism must be challenged if we want to make climate progress - The Conversation UK - December 22nd, 2021
- DA's Office Issues Progress Report for '21 | News | thepilot.com - Southern Pines Pilot - December 22nd, 2021
- The lockout slogs on with very little progress so far - Camden Chat - December 22nd, 2021
- Oakland Police Making Progress' in Investigation Into Shooting Death of Kevin Nishita - NBC Bay Area - December 22nd, 2021
- Australia wrote to Naval Group noting progress on submarines a week before contract was cancelled - The Guardian Australia - December 22nd, 2021
- Leaving The McDuffie Progress after a very enjoyable 10 years - McDuffie Progress - December 22nd, 2021
- 25 Years of YES!: Hope, Progress, and Setbacks - YES! Magazine - December 22nd, 2021
- NY Jets: 3 ways they can show progress against the Dolphins in Week 15 - NorthJersey.com - December 22nd, 2021